Durable remissions with brentuximab vedotin (SGN-35): Updated results of a phase II study in patients with relapsed or refractory systemic anaplastic large cell lymphoma (sALCL).
B. Pro
Consultant or Advisory Role - Seattle Genetics (U)
Research Funding - Seattle Genetics
R. Advani
Consultant or Advisory Role - Seattle Genetics
Research Funding - Seattle Genetics
P. Brice
Honoraria - Seattle Genetics
Research Funding - Seattle Genetics
N. Bartlett
Consultant or Advisory Role - Seattle Genetics
Research Funding - Seattle Genetics
J. D. Rosenblatt
Research Funding - Seattle Genetics
T. Illidge
Research Funding - Seattle Genetics
J. Matous
Consultant or Advisory Role - Celgene; Cephalon; Millennium
Research Funding - Seattle Genetics
R. Ramchandren
Research Funding - Seattle Genetics
M. A. Fanale
Consultant or Advisory Role - Seattle Genetics
Research Funding - Seattle Genetics
J. M. Connors
Research Funding - Seattle Genetics
Y. Yang
Employment or Leadership Position - Seattle Genetics
Stock Ownership - Seattle Genetics
E. L. Sievers
Employment or Leadership Position - Seattle Genetics
Stock Ownership - Seattle Genetics
D. A. Kennedy
Employment or Leadership Position - Seattle Genetics
Stock Ownership - Seattle Genetics
A. R. Shustov
Honoraria - Millennium
Research Funding - Seattle Genetics